Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Clinical evidence

Himalayas-1

36 evidence topics · 13 sources

Objective
Location and study date
Registry status and dates
Study characteristicQuoted record
Overall status“Recruiting”
Study start (actual)“2026-08-03”
Primary completion (estimated)“2028-03”
Study completion (estimated)“2030-09”
First posted“2026-07-23”
Study design
Eligibility criteria
Treatment
Investigational and control regimens
Study drug and armQuoted dose and schedule
Rinzimetostat (investigational arm)“400 mg once daily (QD)”
Darolutamide (investigational arm and physician's choice)“600 mg twice daily (BID)”
Enzalutamide (physician's choice)“160 mg once daily (QD)”
Docetaxel (physician's choice)“75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles”
Study outcomes
Rationale for using radiographic progression-free survival by blinded independent central review as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: design and data limitations
  • No Himalayas-1 results are available. The registry lists the trial as “Recruiting”, with an actual start of 2026-08-03 and estimated primary completion in 2028-03; the design information comes from the registry record, ORIC press releases and filings, and a trial-in-progress poster hosted on the ORIC website.
  • The trial is open label, with no masking (“None (Open Label)”). The primary endpoint, rPFS, is assessed by blinded independent central review per RECIST 1.1 for soft tissue and PCWG3 for bone.
  • The control is a prespecified physician’s choice of an ARPI or docetaxel. Participants assigned to the ARPI control undergo a second 1:1 randomization to darolutamide or enzalutamide, so darolutamide is given in the investigational arm and in part of the control arm; randomization is stratified by control category, prior docetaxel in mCSPC, and hepatic metastases.
  • Overall survival is a key secondary endpoint, formally tested only if the primary rPFS analysis is statistically significant. A consensus statement describes the association between rPFS and overall survival as “still being investigated”; a trial-level analysis of 143 randomized trials in advanced prostate cancer concluded that commonly used clinical end points “are not clear valid surrogate end points for OS”, while an analysis of 11 randomized trials supported rPFS as a valid intermediate endpoint in first-line ARPI-naive mCRPC, a population that differs from the post-abiraterone population of Himalayas-1.
  • Eligibility limits the population to participants with ECOG performance status 0 or 1 and adequate organ function, and excludes brain metastases, clinically significant cardiovascular disease, active inflammatory gastrointestinal disease, and prior treatment with ARPIs other than abiraterone, chemotherapy other than docetaxel for mCSPC, radioligand therapy, PARP monotherapy, or PRC2 inhibitors.
  • The 400 mg dose was selected from phase 1b dose-optimization data in 18 participants at 400 mg and 15 at 600 mg. ORIC conducts and sponsors the trial, and Bayer supplies darolutamide.